European Journal of Medicinal Chemistry p. 22 - 31 (2019)
Update date:2022-08-02
Topics:
Ndikuryayo, Ferdinand
Kang, Wei-Ming
Wu, Feng-Xu
Yang, Wen-Chao
Yang, Guang-Fu
Involved in the tyrosine degradation pathway, 4-hydroxyphenylpyruvate dioxygenase (HPPD) is an important target for treating type I tyrosinemia. To discover novel HPPD inhibitors, we proposed a hydrophobicity-oriented drug design (HODD) strategy based on the interactions between HPPD and the commercial drug NTBC. Most of the new compounds showed improved activity, compound d23 being the most active candidate (IC50 = 0.047 μM) with about 2-fold more potent than NTBC (IC50 = 0.085 μM). Therefore, compound d23 is a potential drug candidate to treat type I tyrosinemia.
View MoreVanderArk International Limited
Contact:86-10-82437576
Address:Qing He
puyang hongda shengdao new material co.,ltd.
Contact:+86-393- 4896278
Address:No.29 East Zhongyuan Road
Jinan Decheng Hemu Medical Technology Co.,Ltd.
Contact:+86-531-68650525
Address:NO.554 Zhengfeng Road High-new Technology Development Zone
Suzhou Credit International Trading Co., Ltd
Contact:+86-512-65398039
Address:Qingdeng, Hightech. District, Suzhou
Zibo Jujin Chemical Industry Co., Ltd.(Dongming Jujin Chemical Industry Co., Ltd. )
Contact:+86-533-2975022
Address:No.99 Shanquan Road, Zhangdian District
Doi:10.1016/j.tet.2011.05.109
(2011)Doi:10.1007/BF00472493
(1990)Doi:10.1021/jacs.8b04581
(2018)Doi:10.1080/10426507.2010.511512
(2011)Doi:10.1021/ol201930e
(2011)Doi:10.2174/157017811796064485
(2011)